NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 348 filers reported holding NEKTAR THERAPEUTICS in Q4 2018. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $77,000 | -61.5% | 4,521 | -47.7% | 0.01% | -71.9% |
| Q2 2020 | $200,000 | -10.3% | 8,646 | +70.5% | 0.03% | -43.9% |
| Q4 2018 | $223,000 | -26.9% | 5,072 | +1.4% | 0.06% | -24.0% |
| Q3 2018 | $305,000 | +2.0% | 5,002 | -18.4% | 0.08% | -16.7% |
| Q2 2018 | $299,000 | +147.1% | 6,133 | +21.2% | 0.09% | +130.8% |
| Q3 2017 | $121,000 | – | 5,059 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |